Feedback

Epigral Limited Announces Board Meeting Outcomes and Financial Results for Q1 FY2025

Ahmedabad, July 24, 2024 — Epigral Limited (formerly known as Meghmani Finechem Limited), a leading manufacturer and seller of Chloro Alkali & its Derivatives, has announced the outcomes of its Board of Directors meeting held today. Key decisions and financial disclosures were made during the meeting.

Key Decisions and Disclosures

Financial Results:

• The Board of Directors approved the Un-Audited Standalone and Consolidated Financial Results for the first quarter ended June 30, 2024.
• The Un-Audited Financial Results along with the Limited Review Report issued by M/s. S R B C & CO LLP, Statutory Auditors of the Company, are enclosed.

Board Meeting Details:

• The meeting commenced at 11:00 a.m. and concluded at 1:00 p.m. at the Registered Office of the Company situated in Ahmedabad.

The above information is also available on the company's website and has been submitted to BSE Limited and National Stock Exchange of India Limited.

Contact Information:

• Registered Office: "Epigral Tower", 8/h Safal Profitaire, Corporate Road, Prahladnagar, Ahmedabad - 380 015.
• Phone: +91 265 3534200
• Email: info@dacl.co.in
• Website: www.dacl.co.in
• CIN: L24100GJ2007PLC051717

For further information:

• Company Secretary & Compliance Officer: Gaurang Trivedi
• Membership No.: 22307
• Email: info@dacl.co.in

Financial Highlights for Q1 FY2025

Standalone Financial Results (₹ in crores):

• Revenue from operations: ₹651.20 (Q1 FY25)
• Total income: ₹653.60 (Q1 FY25)
• Profit before tax: ₹131.10 (Q1 FY25)
• Profit after tax: ₹86.01 (Q1 FY25)

Consolidated Financial Results (₹ in crores):